The concern involves certain medicines, not simply osteoporosis
Antiresorptive medicines, including bisphosphonates and denosumab, play an important role in preventing fractures. They can rarely be associated with medication-related osteonecrosis of the jaw, in which jawbone is damaged and healing is difficult. That is why dentists ask about treatment history. Not every osteoporosis medicine carries the same risk.[1]
This complication can occur in association with procedures involving bone, such as extraction, but can also occur without dental surgery. Avoiding dental care is therefore not a guarantee of safety. Controlling inflammation and planning necessary treatment appropriately are important.[1][4]
'Injection or tablet?' is not enough information
Medicines in the same class may be used at different doses and intervals for osteoporosis and cancer-related conditions. Purpose, duration, other medicines, general health and oral inflammation all contribute to risk assessment. Classifying every tablet as safe and every injection as risky is inaccurate.[2]
Bring the exact name, when treatment began, the most recent dose and the next planned dose. Include medicines used in the past and later stopped. If you only remember it as a 'bone injection,' your prescribing clinic or pharmacy can help identify it.[2]
Implant suitability depends on the mouth as well
The American Dental Association states that antiresorptive therapy for osteoporosis does not appear to be an absolute contraindication to implants, while noting the need for more research into long-term outcomes. This does not mean that everyone taking these medicines can undergo the same operation.[1]
Assessment includes whether a tooth can be retained, the extent of extraction or grafting, whether gum inflammation is controlled and alternative prosthetic options. If surgery is chosen, healing and follow-up care should be discussed too. The choice requires understanding both risks and benefits.[2]
A short drug holiday is not a universal solution
The 2022 AAOMS position paper describes insufficient evidence and continuing controversy over the benefits of a drug holiday for preventing jaw osteonecrosis. A blanket rule to stop treatment for a few months before dental care cannot apply to every drug or patient.[2]
Denosumab in particular carries a safety warning about increased vertebral fracture risk after unplanned interruption or delayed treatment. If a dental procedure requires coordination, the prescriber and dentist should plan it together. Do not postpone injections or skip doses yourself.[3]
Practical preparation before and after treatment
Maintain oral hygiene, attend check-ups and do not leave painful or swollen areas untreated. There is no need to conceal the medicine or avoid all dental care because of it. Giving the information early helps the team choose the appropriate approach and timing.[1]
Seek assessment if a wound heals poorly, or you develop swelling, pus, persistent pain or a change that looks like exposed bone. These symptoms do not automatically mean jaw osteonecrosis, but they need checking. A time period in a diagnostic definition is not an instruction to wait that long at home.[4]
Research and institutional sources
- American Dental Association. Osteoporosis Medications and Medication-Related Osteonecrosis of the Jaw.View source ↗ADA clinical guidance on osteoporosis medicines and implant assessment.
- Ruggiero SL, et al. AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022;80(5):920–943.View source ↗Specialist position paper on individual risk factors and uncertainty about drug holidays.
- MHRA. Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment. 2020.View source ↗Regulatory safety warning on unplanned interruption or delay of denosumab.
- NIDCR. Osteonecrosis of the Jaw.View source ↗NIDCR information on jaw osteonecrosis symptoms and assessment.
Bracketed numbers in the text link to these sources. This article provides general health information; individual diagnosis and treatment plans are determined after a clinical consultation.
